Efficacy of Dual Therapies vs. Quadritherapies in the Eradication of Helicobacter pylori in Latin America
DOI:
https://doi.org/10.52787/agl.v52i3.246Keywords:
Helicobacter pylori, antibioticsAbstract
Helicobacter pylori (H. pylori) infection is a global health problem. Its presence has been associated with the development of digestive pathologies, including peptic ulcer and gastric cancer (GC), and extradigestive pathologies, such as idiopathic thrombocytopenic purpura, among others. There are specific indications for its eradication and, as it is considered a type I carcinogen by the World Health Organization (WHO), massive eradication is currently being considered as a primary prevention strategy to reduce GC incidence and mortality in countries with intermediate (10-20 per 100,000 inhabitants) or high (> 20 per 100,000 inhabitants) prevalence rates. There are different eradication schemes based on proton pump inhibitors and the combination of at least two antibiotics, with or without bismuth, for 14 days.1
References
-1. Villalón A, Reyes D, Ortiz J, Gándara V, Díaz LA, Chahuán J, Pizarro M y Riquelme A. Tratamiento y manejo de la infección por Helicobacter pylori. Gastroenterol Latinoam. 2020;31(3):136-46.
-2. Castaño Llano R, et al. Erradicación de primera línea de Helicobacter pylori con terapia dual de altas dosis versus terapia cuádruple con bismuto por 14 días: estudio multicéntrico, prospectivo y aleatorizado. Acta Gastroenterol Latinoam. 2022;52(2):241-50
-3. Greenberg ER, Anderson GL, Morgan DR, Torres J, et al. 14- day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. www.thelancet.com Publicado en línea en: www.thelancet.com - DOI: 10.1016/S0140-6736(11)60825-8
-4. Arenas A, Serrano C, Quiñones L, Harris P, Sandoval M, Lavanderos M, et al. High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and metaanalysis. Sci Rep. 2019;9:20070.
-5. Muhammad Miftahussurur et al. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic. Am J Trop Med Hyg. 2017;96(5):1050-9. DOI: 10.4269/ajtmh.16-0729
-6. Ogata SK, et al. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J Pediatr Gastroenterol Nutr. 2013;56(6):645-8. DOI: 10.1097/MPG.0b013e31828b3669
-7. Camorlinga-Ponce M, et al. Phenotypic and Genotypic Antibiotic Resistance Patterns in Helicobacter pylori Strains From Ethnically Diverse Population in México. Front Cell Infect Microbiol. 2021;10:539115. DOI: 10.3389/fcimb.2020.539115.eCollection 2020.
-8. Mannion A, Dzink-Fox J, Shen Z, Piazuelo MB, Wilson KT, Correa P, Peek Jr RM, Camargo MC, Fox JG. Helicobacter pylori Antimicrobial Resistance and Gene Variants in Highand Low-Gastric-Cancer-Risk Populations. J Clin Microbiol. 202120;59(5):e03203-20. DOI: 10.1128/JCM.03203-20
-9. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30.
-10. Peter Malfertheiner, Francis Megraud, Theodore Rokkas, Javier P Gisbert et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;0:1-39. DOI: 10.1136/gutjnl-2022-327745
-11. Reyes D., Ortiz J, Fuentes-López E, Budnik S, et al. Terapias cuádruples son superiores a terapia triple estándar en primera línea de erradicación de Helicobacter pylori en Chile, Gastroenterología y Hepatología. Disponible en: https://doi.org/10.1016/j.gastrohep.2021.11.010
-12. González-Hormazábal P, Arenas A, Serrano C, Pizarro M, Fuentes-López E, Arnold J, Berger Z, Musleh M, Valladares H, Lanzarini E, Jara L, Castro VG, Camargo MC, Riquelme A. Prevalence of Helicobacter pylori antimicrobial resistance among patients recruited in endoscopy units in Santiago, Chile. Arch Med Res. 2021:S0188-4409(21)00034-5. DOI: 10.1016/j.arcmed.2021.01.011
-13. Nyssen OP, Bordin D, Tepes B, et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021;70(1):40-54. DOI: 10.1136/gutjnl-2020-321372
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Arnoldo Riquelme, Margarita Pizarro
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
